Chronic constipation: New diagnostic and treatment approaches

Therapeutic Advances in Gastroenterology

Volumn 5, Issue 4, 2012, Pages 233-247

  Lacy, Brian E ^a   Levenick, John M ^b   Crowell, Michael ^c  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^b Section of Vascular Surgery   (Lebanon)

^c MAYO CLINIC   (United States)

Author keywords

Anorectal manometry; Constipation; Guanylate cyclase; Linaclotide; Lubiprostone; Plecanitide; Prucalopride; Rome criteria; Velusetrag; Wireless motility capsule

Indexed keywords

A 3309; CHENODEOXYCHOLIC ACID; GASTROINTESTINAL AGENT; LINACLOTIDE; PLECANATIDE; PRUCALOPRIDE; UNCLASSIFIED DRUG; VELUSETRAG;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ANORECTAL PRESSURE; CHRONIC CONSTIPATION; CHRONIC DISEASE; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); COLON MOTILITY; CONSTIPATION; DIAGNOSTIC APPROACH ROUTE; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; DIARRHEA; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; ELECTRONIC SENSOR; FLATULENCE; HEADACHE; HUMAN; NAUSEA; NONHUMAN; PAIN; PREVALENCE; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE; TREATMENT OUTCOME;

EID: 84863443935     PISSN: 1756283X     EISSN: 17562648     Source Type: Journal    
DOI: 10.1177/1756283X12443093     Document Type: Article

References (53)

1. Beattie D.T. Armstrong S.R. Shaw J.P. Marquess D. Sandlund C. Smith J.A. et al. (2008) The in vivo gastrointestinal activity of TD-5108, a selective 5-HT (4) receptor agonist with high intrinsic activity. Naunyn Schmiedebergs Arch Pharmacol 378: 139–147.
2. Brandt L.J. Prather C.M. Quigley E.M.M. Schiller L.R. Schoenfeld P. Talley N.J. (2005) Systematic review on the management of chronic constipation in North America. Am J Gastroenterol 100 (1): S5–S22.
3. Bryant A.P. Busby R.W. Bartolini W.P. Cordero E.A. Hannig G. Kessler M.M. et al. (2010) Linaclotide is a potent and selective guanylate cyclase C agonist that elicits pharmacological effects locally in the gastrointestinal tract. Life Sciences 86: 760–765.
4. Bryant A.P. Busby R.W. Cordero E.A. Tobin J.V. Bartolini W.P. Beaufrand C. et al. (2005) Md-1100, a therapeutic agent in development for the treatment of IBS-C, enhances intestinal secretion and transit, decreases visceral pain and is minimally absorbed in rats. Gastroenterology 128: A464–A464.
5. Busby R.W. Bryant A.P. Bartolini W.P. Cordero E.A. Hannig G. Kessler M.M. et al. (2010) Linaclotide, through activation of guanylate cyclase C, acts locally in the gastrointestinal tract to elicit enhanced intestinal secretion and transit. Eur J Pharmacol 649: 328–335.
6. Busby R.W. Bryant A.P. Cordero E.A. Kessler M.M. Pierce C.M. Tobin J.V. et al. (2005) The molecular target of MD-1100 is guanylate cyclase-C (gc-C), an apical receptor on intestinal epithelial cell. Gastroenterology 128: A464–A464.
7. Camilleri M. Kerstens R. Rykx A. Vandeplassche L. (2008) A placebo-controlled trial of prucalopride for severe chronic constipation. N Engl J Med 358: 2344–2354.
8. Camilleri M. Thorne N.K. Ringel Y. Hasler W.L. Kuo B. Esfandyari T. et al. (2010) Wireless pH-motility capsule for colonic transit: prospective comparison with radiopaque markers in chronic constipation. Neurogastroenterol Motil 22: 874–882, e233.
9. Cash B.D. Lacy B.E. (2006) Systematic review: FDA-approved prescription medications for adults with constipation. Gastroenterol Hepatol 2: 736–749.
10. Choung R.S. Branda M.E. Chitkara D. Shah N.D. Katusic S.K. Locke G.R. 3rd et al. (2011) Longitudinal direct medical costs associated with constipation in women. Aliment Pharmacol Ther 33: 251–260.
11. Crowell M.D. Harris L.A. Lunsford T.N. Di Baise J.K. (2009) Emerging drugs for chronic constipation. Expert Opin Emerg Drugs 14: 493–504.
12. Currie M.G. Fok K.F. Kato J. Moore R.J. Hamra F.K. Duffin K.L. et al. (1992) Guanylin: an endogenous activator of intestinal guanylate cyclase. Proc Natl Acad Sci U S A 89: 947–951.
13. Eutamene H. Bradesi S. Larauche M. Theodorou V. Beaufrand C. Ohning G. et al. (2010) Guanylate cyclase C-mediated antinociceptive effects of linaclotide in rodent models of visceral pain. Neurogastroenterol Motility 22 (3): 312–E83.
14. Everhart J.E. Ruhl C.E. (2009) Burden of digestive diseases in the United States part II: lower gastrointestinal diseases. Gastroenterology 136: 741–754.
15. Frank L. Kleinman L. Farup C. Taylor L. Miner P. Jr (1999) Psychometric validation of a constipation symptom assessment questionnaire. Scand J Gastroenterol 34: 870–877.
16. Goldberg M.R. Li Y.P. Pitzer K. Johanson J.F. Mangel A.W. Kitt M.M. (2008) TD-5108, a selective 5-HT4 agonist, is consistently better than placebo regardless of response definition in patients with chronic constipation. Gastroenterology 134: A545–A545.
17. Hamra F.K. Forte L.R. Eber S.L. Pidhorodeckyj N.V. Krause W.J. Freeman R.H. et al. (1993) Uroguanylin: structure and activity of a second endogenous peptide that stimulates intestinal guanylate cyclase. Proc Natl Acad Sci U S A 90: 10464–10468.
18. Harari D. Gurwitz J.H. Avorn J. Bohn R. Minaker K.L. (1997) How do older persons define constipation? Implications for therapeutic management. J Gen Intern Med 12: 63–66.
19. Herz M.J. Kahan E. Zalevski S. Aframian R. Kuznitz D. Reichman S. (1996) Constipation: a different entity for patients and doctors. Fam Pract 13: 156–159.
20. Higgins P.D.R. Johanson J.E. (2004) Epidemiology of constipation in North America: A systematic review. Am J Gastroenterol 99: 750–759.
21. Irvine E.J. Ferrazzi S. Pare P. Thompson W.G. Rance L. (2002) Health-related quality of life in functional GI disorders: Focus on constipation and resource utilization. Am J Gastroenterol 97: 1986–1993.
22. Janssen Research Foundation (1999) Prucalopride Investigator's Brochure, 7th edn. Janssen Research Foundation, p. 90.
23. Johnston J.M. Kurtz C.B. Drossman D.A. Lembo A.J. Jeglinski B.I. MacDougall J.E. et al. (2009) Pilot study on the effect of linaclotide in patients with chronic constipation. Am J Gastroenterol 104: 125–132.
24. Jones M.P. Post J. Crowell M.D. (2007) High-resolution manometry in the evaluation of anorectal disorders: a simultaneous comparison with water-perfused manometry. Am J Gastroenterol 102: 850–855.
25. Kuo B. Maneerattanaporn M. Lee A.A. Baker J.R. Wiener S.M. Chey W.D. et al. (2011) Generalized transit delay on wireless motility capsule testing in patients with clinical suspicion of gastroparesis, small intestinal dysmotility, or slow transit constipation. Dig Dis Sci 56: 2928–2938.
26. Lacy B.E. Chey W.D. (2009) Lubiprostone: chronic constipation and irritable bowel syndrome with constipation. Expert Opin Pharmacother 10: 143–152.
27. Lembo A. Camilleri M. (2003) Chronic constipation. N Engl J Med 349: 1360–1368.
28. Lembo A.J. Kurtz C.B. MacDougall J.E. Lavins B.J. Currie M.G. Fitch D.A. et al. (2010) Efficacy of linaclotide for patients with chronic constipation. Gastroenterology 138 (3): 886–95.
29. Lembo A.J. Schneier H.A. Shiff S.J. Kurtz C.B. MacDougall J.E. Jia X.W.D. et al. (2011) Two randomized trials of linaclotide for chronic constipation. N Engl J Med 365: 527–536.
30. Longstreth G.F. Thompson W.G. Chey W.D. Houghton L.A. Mearin F. Spiller R.C. (2006) Functional bowel disorders. Gastroenterology 130: 1480–1491.
31. Manini M.L. Camilleri M. Goldberg M. Sweetser S. McKinzie S. Burton D. et al. (2010) Effects of Velusetrag (TD-5108) on gastrointestinal transit and bowel function in health and pharmacokinetics in health and constipation. Neurogastroenterol Motil 22: 42–49, e47–48.
32. Martin B.C. Barghout V. Cerulli A. (2006) Direct medical costs of constipation in the United States. Manag Care Interface 19 (12): 43–49.
33. Mok H.Y. Bell G.D. Dowling R.H. (1974) Effect of different doses of chenodeoxycholic acid on bile-lipid composition and on frequency of side-effects in patients with gallstones. Lancet 2: 253–257.
34. Muller-Lissner S.A. Kamm M.A. Scarpignato C. Wald A. (2005) Myths and misconceptions about chronic constipation. Am J Gastroenterol 100: 232–242.
35. Nyrop K.A. Palsson O.S. Levy R.L. Korff M.V. Feld A.D. Turner M.J. et al. (2007) Costs of health care for irritable bowel syndrome, chronic constipation, functional diarrhoea and functional abdominal pain. Aliment Pharmacol Ther 26: 237–248.
36. O'Keefe E.A. Talley N.J. Tangalos E.G. Zinsmeister A.R. (1992) A bowel symptom questionnaire for the elderly. J Gerontol 47 (4): M116–M121.
37. Quigley E.M. Vandeplassche L. Kerstens R. Ausma J. (2009) Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation--a 12-week, randomized, double-blind, placebo-controlled study. Aliment Pharmacol Ther 29: 315–328.
38. Rao A.S. Wong B.S. Camilleri M. Odunsi-Shiyanbade S.T. McKinzie S. Ryks M. et al. (2010) Chenodeoxycholate in females with irritable bowel syndrome-constipation: a pharmacodynamic and pharmacogenetic analysis. Gastroenterology 139: 1549–1558, 1558 e1541.
39. Rao S.S. Kuo B. McCallum R.W. Chey W.D. Di Baise J.K. Hasler W.L. et al. (2009) Investigation of colonic and whole-gut transit with wireless motility capsule and radiopaque markers in constipation. Clin Gastroenterol Hepatol 7: 537–544.
40. Sandler R.S. Drossman D.A. (1987) Bowel habits in young adults not seeking health care. Dig Dis Sci 32: 841–845.
41. Shah N.D. Chitkara D.K. Locke G.R. Meek P.D. Talley N.J. (2008) Ambulatory care for constipation in the United States, 1993–2004. Am J Gastroenterol 103: 1746–1753.
42. Shailubhai K. Barrow L. Talluto C. et al. (2011) Plecanatide, a Guanylate Cyclase C Agonist, Improves Bowel Habits and Symptoms Associated with Chronic Constipation in a Phase IIa Clinical Study. ACJ 11(S2): 1174.
43. Simren M. Bajor A. Gillberg P.G. Rudling M. Abrahamsson H. (2011) Randomised clinical trial: The ileal bile acid transporter inhibitor A 3309 vs. placebo in patients with chronic idiopathic constipation - a double-blind study. Aliment Pharmacol Ther 34: 41–50.
44. Solinga R. Kessler M. Busby R. Currie M. (2011) A comparison of the physical and pharmacological properties of plecanatide (SP-304) and the human hormone uroguanylin. ACJ 11(S2): P332.
45. Sonnenberg A. Chang J. (2008) Time trends of physician visits for Crohn's disease and ulcerative colitis in the United States, 1960–2006. Inflammatory Bowel Dis 14: 249–252.
46. Sun S.X. Dibonaventura M. Purayidathil F.W. Wagner J.S. Dabbous O. Mody R. (2011) Impact of chronic constipation on health-related quality of life, work productivity, and healthcare resource use: an analysis of the National Health and Wellness Survey. Dig Dis Sci 56: 2688–2695.
47. Tack J. Camilleri M. Chang L. Chevy W.D. Galligan J.J. Lacy B.E. et al. (2012) Systematic review: cardiovascular safety profile of 5-HT4 agonists developed for GI disorders. Aliment Pharmacol Ther, in press.
48. Tack J. van Outryve M. Beyens G. Kerstens R. Vandeplassche L. (2009) Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives. Gut 58: 357–365.
49. Thompson W.G. Longstreth G.F. Drossman D.A. Heaton K.W. Irvine E.J. Muller-Lissner S.A. (1999) Functional bowel disorders and functional abdominal pain. Gut 45(Suppl. 2): II43–II47.
50. Wald A. Scarpignato C. Kamm M.A. Mueller-Lissner S. Helfrich I. Schuijt C. et al. (2007) The burden of constipation on quality of life: results of a multinational survey. Aliment Pharmacol Ther 26: 227–236.
51. Whitehead W.E. Drinkwater D. Cheskin L.J. Heller B.R. Schuster M.M. (1989) Constipation in the elderly living at home. Definition, prevalence, and relationship to lifestyle and health status. J Am Geriatr Soc 37: 423–429.
52. Wong B.S. Camilleri M. McKinzie S. Burton D. Graffner H. Zinsmeister A.R. (2011) Effects of A3309, an ileal bile acid transporter inhibitor, on colonic transit and symptoms in females with functional constipation. Am J Gastroenterol 106: 2154–2164.
53. Young R.J. Beerman L.E. Vanderhoof J.A. (1998) Increasing oral fluids in chronic constipation in children. Gastroenterol Nurs 21: 156–161.